

AD _____

Award Number DAMD17-93-V-3013

TITLE: Neural Responses to Injury: Prevention, Protection, and Repair

Subtitle: Neurochemical Protection of the Brain, Neural Plasticity and Repair

PRINCIPAL INVESTIGATOR: Nicolas G. Bazan, M.D., Ph.D.

CONTRACTING ORGANIZATION: Louisiana State University
School of Medicine
New Orleans, Louisiana 70111-2822

REPORT DATE: October 1998

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5102

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 1

20000223 005

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188


Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1998		3. REPORT TYPE AND DATES COVERED Final (20 Sep 93 - 19 Sep 98)	
4. TITLE AND SUBTITLE Neural Responses to Injury: Prevention, Protection, and Repair				5. FUNDING NUMBERS DAMD17-93-V-3013	
6. AUTHOR(S) Nicolas G. Bazan, M.D., Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Louisiana State University School of Medicine New Orleans, Louisiana 70111-2822				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Subtitle: Neurochemical Protection of the Brain, Neural Plasticity and Repair					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)					
14. SUBJECT TERMS Prevention, Injury				15. NUMBER OF PAGES 64	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army.

- () Where copyrighted material is quoted, permission has been obtained to use such material.
- () Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
- () Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
- (✓) In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).
- (✓) For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
- () In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
- () In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH guidelines for Research Involving Recombinant DNA Molecules.
- () In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



Investigator Signature

Date

ANIMAL USE
SEPTEMBER 20, 1997 THROUGH SEPTEMBER 19, 1998

DAMD17-93-V-3013

The experimental animals used during this period for the project, Neural Responses to Injury: Prevention, Protection, and Repair, **Subproject: Neurochemical Protection of the Brain, Neural Plasticity and Repair**, are as follows:

Species	Number Allowed	Number Used	LSU IACUC#
Rat (Sprague-Dawley)	125	125	1045, 1046, 1482

Investigator Signature



TRAUMATIC BRAIN INJURY

Introduction

The development of chronic epilepsy is a very serious complication of head injury, neurodegenerative diseases, brain tumors, and exposure to neurotoxic agents. Head injury is often associated with loss of short-term memory, indicating trauma to the hippocampal formation, the brain region most commonly associated with epileptic brain damage. Underlying the formation of epilepsy (epileptogenesis) is proposed to be a vicious cycle initiated by the loss of neurons. In an attempt to repair and/or replace lost synaptic connections, the brain can develop aberrant synaptic circuits that permit the propagation and amplification of waves of excitatory neurotransmission, eventually resulting in prolonged or repeated seizures (status epilepticus). The massive amounts of excitatory amino acids released during these episodes can stimulate further neuronal loss (excitotoxic damage), the formation of more aberrant synaptic circuits, and further seizures.

It is now apparent, however, that even brief, sporadic seizures, such as those induced in the kindling model of epileptogenesis, may induce neuronal loss in vulnerable brain regions¹. Kindling is a widely-used animal model of chronic epilepsy in which repetition of a given electrical stimulus to a discrete focal point in the limbic system of the brain gives rise to a fixed sequence of events. This sequence is characterized by a progression in both the duration of the electrographic seizures (afterdischarges), and in the severity of the accompanying behavioral seizures until a stable plateau is reached. Subsequently, the same stimulus, which at the beginning of the process elicited a minimal afterdischarge, will then elicit a protracted afterdischarge and stereotyped generalized convulsions characteristic of kindled seizures². Kindled seizures can then subsequently be elicited in treated animals even when the stimulus is withheld for several months, which establishes that chronic alterations have occurred in the kindled brain analogous to those in the epileptic human brain. Hippocampal kindling has been shown to induce collateral sprouting of mossy fibers, and progressive loss of interneurons in the hilus of the dentate gyrus, and in the CA1^{1,3}.

Kindling is an experimental model of mesial temporal lobe epilepsy (MTLE), whereby repeated application of initiative subconvulsive electrical stimulation results in progressive motor seizures, culminating in generalized clonic motor seizures³⁻⁵. We believe that changes of certain gene expressions are required for kindling epileptogenesis and maintenance of kindling effect, and interference with expression of these genes will inhibit kindling epileptogenesis. In this project, we hypothesize that: 1) A single kindling stimulation induces acute gene expression. 2) Repetitive stimulation induces accumulation of acute response gene products, which in turn activate sustained neurotrophic gene expression and lead to synaptic reorganization, neuron death and proliferation. 3) Platelet activation factor (PAF) mediates stimulation of induced gene expression in kindling.

The Rapid Hippocampal Kindling Model of Traumatic Head Injury

Kindling was introduced by Goddard and his colleagues early in 1969². It is defined as the phenomenon in which repeated administration of an initially subconvulsive electrical stimulus to animal brain results in progressive intensification of seizure activity, culminating in a generalized convulsion. Because behavior and physiology manifestation of limbic kindling resembles human mesial lateral temporal epilepsy (MLTE), kindling was accepted as an experimental model for temporal lobe epilepsy soon after its introduction^{6,7}.

Kindling can be achieved in a variety of brain regions², but amygdala and hippocampus are most frequently studied. Kindling from amygdala was found to be most efficient, this explains the reason why this model is most extensively used. In kindling from amygdala and many other regions, morphology and molecular biological alteration were found mainly in hippocampus. This included neuron loss^{1,3,8-11}, mossy fiber sprouting^{8,10}, modification of neurotransmitter receptors¹³⁻¹⁶, and induction of gene expression¹⁷⁻²¹, suggesting that hippocampus plays a very important role in kindling. Also hippocampus sclerosis is the main pathological founding in human MLTE. Surgical removal of hippocampus will reduce or eliminate epileptic seizure of MLTE patients, implying hippocampus is critical to seizure origin, and probably it is the main site of seizure origin²². In this project we use hippocampus kindling in order to simulate human epileptic seizure originated in hippocampus.

There are a variety of stimulation protocols to induce kindling in rats. The classical kindling uses tetanic stimuli with frequencies of 60 Hz and train duration of 1 second, delivered daily². Using this stimulation protocol, hippocampus kindling requires as long as 50 to 77 days. Loathman²³ in 1985 developed a rapidly hippocampal kindling protocol. His protocol was based upon the administration of a 10 second 10, 25, 50 Hz train of stimulation every 5 minutes during a period of 6 hours. This protocol was found capable of inducing progressive seizure, but the seizure intensity was not increasing as smoothly as classical kindling. In 1993, he develops another improved rapid hippocampal kindling protocol²⁴. This protocol differs from the former one on that the stimulation was given 12 times daily for a total of 4 days with an inter-stimulus interval of 30 minutes. Hippocampal kindling using this stimulation protocol progressed rather smoothly and smaller variations were observed between individual animals.

The Requirement of Gene Expression Regulation in Kindling

It has been clearly established that kindling can induce neuron loss and mossy fiber sprouting^{1,3,8-11}, but it is still controversial whether kindling epileptogenesis requires neuron loss^{3,8,25,26} or mossy fiber sprouting^{8,10,25}. It is well known that gene expression is required in neuronal apoptosis and neurite growth, so is almost certain that regulation of gene expression is involved in kindling-induced neuronal death and neurite reorganization. Gene expression induction is observed after seizure¹⁷⁻²¹, and inhibition of protein synthesis suppresses kindling development²⁷, suggesting that gene expression is required in kindling development. It is now known that kindling induces both acute and long-term changes in gene expression. Acute gene expression upregulation includes immediate early genes, neurotrophic factors and other genes, which are temporally upregulated few minutes to hours after seizure and back to normal within one day. Immediate early genes such as c-fos^{17,18,20,28}, c-jun^{18,28}, jun-B¹⁸, krox-24¹⁸, NGFI-A (also known as zif-268)²⁹, erg-1³⁰ and tissue-plasminogen activator³¹ are induced within hours after seizure. Neurotrophic factor genes such as BDNF, NGF, NT-3³² and their receptor genes such as trk B and trk C³³ are acutely induced by seizure, while genes such as mineralocorticoid and glucocorticoid receptors³⁴ are also increased after a stimulation-induced seizure. Genes exhibit long term changes after kindling. This includes calcium calmodulin dependent protein kinase II (CaMK II)³⁵, NMDA receptor³⁶, kainate receptor³⁷, AMPA receptor³⁸, GABA_A receptor^{39,40,41}, neuropeptide Y(NPY)⁴², prodynorphin and proenkephalin^{43,44,45}, vasopressin^{46,47},

and ligatin⁴⁸. Most of the above genes do not sustain changes for longer than a few weeks. For those genes such as ligatin that have sustained change of expression, none has been shown to be involved in elevated neuronal excitability. Nevertheless, kindling induced hyper-excitability remains for a few months or, in some cases, for the rest of animals' life², suggesting that kindling is maintained probably not by elevation of certain gene expression, but by the formation of new neural circuits^{49, 50}, apoptosis of existing neurons^{51, 52} and formation of new neurons^{11, 51}. All these process requires temporal upregulation of genes expression that involves apoptosis, neuroprotection, and neurite growth. This is in agreement with the fact that kindling involves transient gene expression regulation and inhibition of protein synthesis to block kindling development²¹.

PAF is a Potential Mediator of Gene Expression in Kindling

Platelet-activating Factor (PAF) was originally identified in the 1970s as a substance released from activated basophils⁵³. It was then detected in a variety of inflammatory and immune-related cells, such as leukocytes, monocytes, macrophages, endothelial cells and platelets⁵⁴. It is a potent mediator in anaphylactic and inflammatory responses⁵⁴, as well as an important substance in reproduction^{56, 57} and development^{57, 58}. In the late 1980s, PAF was also detected in mammalian brain⁵⁹ and shown to be significantly increased after seizure⁶⁰. PAF is synthesized by neurons^{61, 62} and glial cells⁶² in culture, but it is commonly accepted that PAF accumulates in brain tissue after stimulation, mainly originating from neurons⁶³. PAF is implicated in gene induction, ion channel modification, and enzyme activation^{64, 65}, which qualify it to be a potent mediator of gene expression induced by kindling stimulation.

In vitro, PAF is a powerful modulator of proteins and enzymes capable of mediating gene expression in neurons. PAF can activate NF κ B⁶⁶, MAPK^{67, 68}, and modulate NMDA receptor function^{69, 70}. NF κ B is a potent activator of immediate early gene transcription⁷¹; MAPK is responsible for modulation of gene expression⁷²; and, the NMDA receptor is a critical mediator of kindling development⁷³⁻⁸¹ and kindling-induced mossy fiber sprout^{82, 83}. PAF can also enhance glutamate release in LTP⁸⁴, increase intracellular calcium concentration⁸⁵, and promote apoptosis⁸⁶.

There are two known pathways of PAF synthesis in neurons⁸⁷. One is the de novo pathway that utilizes CDPcholine and alkylacetyl glycerol and is catalyzed by a specific

phosphocholinetransferase (PAF-PCT). The other is the remodeling pathway ending with the reaction catalyzed by lyso-PAF acetyltransferase (lyso-PAF AcT), utilizing lyso-PAF, a product of phospholipase A₂ activity, and acetyl-CoA. It has been established that the remodeling pathway is activated in hippocampus during ischemia⁸⁸. Cytosolic phospholipase A₂ is activated by calcium influx after glutamate treatment of neurons⁸⁹, supporting the idea that PAF synthesis is elevated during kindling through remodeling pathways.

PAF has at least two high-affinity binding sites in the brain^{64, 90}, one in synaptosomes, and the other in microsomes. They differ in their antagonists specificity. The synaptosomal site is selectively blocked by an experimental drug, BN52021, and inhibition of PAF binding to this site inhibits PAF mediation of hippocampal LTP. This site corresponds to the G-protein coupled PAF receptor cloned in mammalian or human lung⁹¹, spleen⁹², human leukocytes⁹³ and heart⁹⁴. The microsomal site is blocked by BN50730, and this site is responsible for PAF induced immediate gene expression⁹⁵. The identity of this binding site is still unknown.

COX-2 as a Possible Mediator of PAF-Induced Apoptosis in kindling

There are two isoforms of cyclooxygenases (COX) responsible for prostaglandin synthesis⁹⁶. COX-1 is the constitutive form, while COX-2 is the inducible one. COX-2 is known as a very important mediator in inflammatory response⁹⁶ and an anti-apoptotic enzyme in cancer growth⁹⁷. Recently, COX-2 was found to mediate neuronal death caused by brain ischemia⁹⁸, seizure⁹⁹ and chochicine toxicity¹⁰⁰. Since PAF antagonists inhibit COX-2 gene transcription after seizure¹⁰¹, it is postulated that COX-2 mediates PAF induction of neuronal apoptosis during kindling.

BODY

Previous work

In previous reports (years 1 & 2), we have shown that COX 2 mRNA and protein levels are up-regulated during cryogenically-induced vasogenic brain edema in rats. COX 2 protein levels peak at 4-5 hours post-injury, 2-3 hours after the peak in COX 2 mRNA levels. The induction is sustained up to 24 hours post-injury. A role for platelet-activating factor in COX 2 activation was implied by the ability of the specific intracellular PAF receptor antagonist BN 50730, and the novel PAF antagonist LAU 503, to block this induction at least partially. PAF

receptor antagonists and glucocorticoids (inhibitors of COX 2 up-regulation) also reduce blood-brain barrier breakdown in this model, implying a role for PAF-induced COX 2 activation in edema formation. We used electrophoretic mobility shift assays (EMSAs) to show that the DNA binding activities from rat brain nuclear extracts specific for AP2, CREB, GAS/ISRE and NFkB decreased during the cryogenic injury. We presented evidence of a novel DNA binding protein in rat brain nuclear protein extracts which binds to a region (-460 to -258) of the COX 2 promoter. This protein was present only in uninjured brains, and disappeared during cryogenic injury. We speculated that this protein represented a repressor of COX 2 expression, the removal of which during injury was an important step in the increase of COX 2 transcriptional activity.

In years 2 and 3, the rapid kindling model was used to assess the effects of the PAF antagonist BN 50730 on the development of electrographic and behavioral seizures. Drug-treated animals showed a statistically-significant lower increase in evoked after-discharge duration (ADD), and a slower development of behavioral seizures. Interestingly, ADDs were not significantly different between drug-treated and control groups after the first day, but diverged later during the process. This indicated that BN 50730 was not acting as an anticonvulsant, but was inhibiting some process underlying the development of kindled seizures. Preliminary histological studies suggested that BN 50730 was protective against cell loss in the hilus of the dentate gyrus. We also determined that, while some initial cell death occurs immediately within the acquisition phase, many nuclei survive throughout the development and retest phases of kindling development. The large drop in hippocampal, dentate gyrus, and hilar cells occurred as a gradual process as a result of continual seizure episodes following the kindling process. We concluded that neural sprouting and rewiring, known to occur early in the kindling process, are either an independent process, separate from that producing apoptosis, or are a continual process that accompanies a slow, low level apoptotic process.

During year 4, we expanded our studies of transcription factor regulation during the brain edema model in the rat by identifying the factors, specifically induced by PAF, that regulate COX 2 promoter activity. This entailed using cell lines in which PAF induces COX 2 transcription. During this project, sequence data for the COX 2 promoter from other species (mouse and human) became available, and there were apparently interspecies variations in promoter structure. Therefore, if COX 2 gene activation were to be a potentially useful therapeutic target, finding it out whether the factors important in COX 2 promoter activation in

our rat model were similar to those activating the human promoter was necessary. For these studies, using for our EMSAs nuclear protein extracts from cell lines in which PAF induces COX 2 expression was necessary. We used a rat glioma/mouse neuroblastoma hybrid cell line (NG108-15), and a human B lymphoblast line (IM9) as our PAF-responsive cell lines.

We also wanted to characterize the putative rat COX 2 repressor protein further, and to learn if a homologous protein was involved in human COX 2 promoter activity. For this we used DNA-magnetic bead affinity technology, designed to isolate and purify proteins that bind to a specific DNA sequence. The ability of PAF to induce the injury-associated nucleoprotein identified in the brain edema model (Progress Report, year 2) was assessed in the cell lines. Nucleoprotein extracts were prepared from NG108-15 and IM9 cells treated for different times with PAF.

Intracerebroventricular injection of rats with BN 50730 before the stimulus inhibited the seizure-induced up-regulation of COX 2 expression in hippocampus, as well as the downregulation of transcription factor activities triggered by seizures, similar to our observations using the brain edema model (Progress Report, year 2). Treatment of IM9 cells with PAF induced a similar pattern of downregulation of the transcription factors AP-2, CRE and NFkB, which is sensitive to BN 50730. We concluded that the PAF response in the human cell line in vitro is qualitatively similar to that of the BN 50730-sensitive response to neurotrauma in the rat.

Objectives, Year 5

Plasticity modifications induced by traumatic head injury or seizures are not well understood. The objective of the current period of work was to use the kindling model of epilepsy to investigate COX-2 (cyclooxygenase-2) and cPLA₂ (cytosolic phospholipase A₂) upregulation of gene transcription. Figure 1 summarizes our hypothesis. Briefly, stimulation induces neuron depolarization and calcium influx, thereby activating cPLA₂. cPLA₂ catalyzes PAF and arachidonic acid (AA) synthesis. PAF further activates gene expression of COX-2 and cPLA₂. AA is a substrate of COX-2 that catalyzes prostaglandin synthesis, inducing neuronal apoptosis. The increased expression of COX-2 and cPLA₂ in neurons acts as positive feedback and, therefore, catalyzes the evident effect on gene expression and apoptosis (Fig 1A). Figure 1B

summarizes our overall hypothesis that COX-2 gene expression induces apoptosis of inhibitory interneurons, whereby establishing an unchecked route of stimulation transmitted from the hippocampus to the motor cortex, resulting in seizure.

Material and Methods

Surgery

Wistar rats weighing 180-350g were anesthetized (ketamine 100 mg/kg, xylazine 10mg/kg, i. p.) and polyimide coated stainless steel bipolar electrodes were stereotactically implanted in the right ventral hippocampus (AP -3.2, ML -5.2, DV -6.5 to dura; according to Pellegrino's atlas published in 1979). The rats were allowed 2 to 4 weeks to recover from surgery.

Kindling

Figure 2A depicts the setup of the kindling model. Adult male Wistar rats were placed in a transparent cage through which we could observe seizure behavior. Figure 2B demonstrates the implantation of the electrode into rat hippocampus. Briefly, a Teflon coated tripolar electrode is implanted into the circled region in right ventral hippocampus. Two ends of the electrode are inserted into the hippocampus, serving the purpose of stimulation and recording, the third end of the electrode is attached to the outside surface of the skull by screws serving as ground. The electrode is firmly cemented to the skull using four small screws. A cable is then connected to the electrode implanted in the right ventral hippocampus of the rats. Kindling electrical stimulation is delivered and after-discharge inside the hippocampus monitored through the same electrode. Kindling stimuli are applied 12 times every other day for 9 Days, with 30 minutes intervals between stimulation (see Figure 3). 59-66 days after kindling initiation, COX-2, COX-1 and cPLA2 mRNA content in hippocampus, cortex, and cerebellum of both sides were measured 2 hours after stimulation using RT-PCR. The seizure behaviors are scored, using the method of Loathman. The ADD are also monitored.

Kindling Confirmation

Kindling was confirmed 55 days after the kindling initiation date, using one or two trains of the same stimulation used in kindling. The animal is considered kindled if a stage 5 seizure is elicited after stimulation. Seizure score is defined as described by Racine et al. (1972):

1. facial clonus, stand still, wet dog shaking
2. head nodding
3. fore limb clonus
4. rearing, loss of balance
5. falling

Sampling and RT-PCR

Four to eleven days after kindling confirmation, the rats were stimulated with one single train of stimulation, and cortex, hippocampus and cerebellum of both sides were sampled 2 hours after stimulation. Total RNA was extracted from the tissues, using RNA STAT-60 from Tel-Test Inc. RT-PCR was performed to determine the mRNA level of COX-2, cPLA₂ and COX-1. G6PDH was used as control.

RESULTS

During the kindling stimulation process, after 0.1 second of electrical stimulus, a recording of EEG electrical activity was produced for up to 12 minutes. At the end of the experiments, computer analysis was produced, and ADD events were compiled and analyzed for duration and frequency. ADD as a function of the number of stimuli is shown in Fig. 4A. The profile reflects a progression in the ADD as a result of repetitive stimulus. The events reached an average maximum duration of 150 sec, which correlated at the same stimulation period with class 4 – class 5 type seizures, as shown in Figure 4B. Seizure classifications were obtained, according to Racine (1972). Per day stimulation produces a progressive increase in seizure response and ADD, and reaches plateau by the end of the stimulation set, but the slope increases as animals approach the fifth stimulation set. After a two week recovery, a single stimulation generated a full scale seizure, confirming that the animal was kindled.

When the COX-2 message was studied in rat hippocampus and cortex of kindled and unkindled animals, receiving a single stimulation and sacrificed after two hours, there was a significant increase in both the right (stimulated site, $p < 0.01$) and left hippocampus ($p < 0.001$) (Fig 5A). However, in cortex, there was a significant increase only in the kindled group (Fig 5B) ($p < 0.01$ for both left and right cortex.) There was not change in COX-1 message in any of the animals studied (data not shown.) Study of cPLA₂ mRNA revealed the same pattern of change as that of COX-2 mRNA in hippocampus (Fig 6A), while not significant changes were obtained in cPLA₂ mRNA in rat cortex (Fig 6B). Gene transcription of COX-2 and cPLA₂ had not significant changes in cerebellum after stimulation of either kindled or non-kindled rats. Changes in left and right sides of cortex and hippocampus revealed no significant differences, indicating changes were not associated with trauma induced by electrode implantation.

Kindled or non-kindled animals were subjected to a single kindling stimulation, then sacrificed in a time course up to 24 hours. The profile analysis for COX-2 mRNA in hippocampus and cortex of both groups are shown in Fig 7B. Hippocampal tissue shows no differences, with the exception of a pronounced peak after 1 hour stimulation. Such differences were not significant. However, a completely different profile is apparent in kindled and non-kindled cortex: kindled cortex shows a two step curve, the first of which peaks after 2 hours, the second at about 12 hours. Figure 7A is a representative agarose gel of COX-2 PCR products.

A time course of expression levels of cPLA₂ mRNA after a single stimulation in kindled rats reveals a differential profile for the hippocampus, as compared to cortex (Fig 8B). The slope of both respective curves run parallel up to four hours, with hippocampus reaching a plateau and remaining slightly over-expressed to 24 hours. Cortex shows a 200% increase by 12 hours, remaining elevated to 24 hours. A representative agarose gel of cPLA₂ PCR products is shown in Fig 8A.

Conclusions

1. Kindling stimulation triggers upregulation of both COX-2 and cPLA₂ genes in both the implanted and the contralateral hippocampus in kindled and non-kindled rats.
2. Only kindled animals show an upregulation of COX-2 expression in cortex. One kindling stimulation: a) in the left hippocampus, results in a sustained upregulation of COX-2 mRNA with no differences between kindled and non-kindled animals; b) in the left cortex, induces a biphasic increase in COX-2 mRNA only in kindled animals, with a sharp peak by 2hr, followed by a second peak at 12 hr and sustained to 24 hr.
3. Kindled and non-kindled animals show the same pattern of changes in cPLA₂ 2 hours after a single stimulation.
4. Time course of cPLA₂ mRNA levels after a single stimulation reveals a differential response between hippocampus and cortex, indicating a different latency to signal-response activity for these tissues.
5. Cortex shows a delayed enhancement of cPLA₂ by 12 hrs, which correlates with the second peak of expression for the COX-2 gene. The delayed over-expression of these two enzymes could be the result of intense neurologic activity. This may implicate the cortex as the final location of recurrent epileptogenesis.

These results may indicate that kindling triggers the establishment of new circuitry, which is involved in generating a significant response in both sides of cortex for COX-2 and cPLA₂.

References

- 1 Cavazos JE, Das I, Sutula TP. Neuronal loss induced in limbic pathways by kindling: evidence for induction of hippocampal sclerosis by repeated brief seizures. *J Neurosci* 1994, 14(5):3106-3121
- 2 Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. *Exp. Neurol.* 1969, 295-330
- 3 Cavazos JE, Sutula JP. Progressive neuronal loss induced by kindling: a possible mechanism for mossy fiber synaptic reorganization and hippocampal sclerosis. *Brain Res* 1990, 527:1-6
- 4 Sander JWAS, Shorvon SD. Epidemiology of the epilepsies. *Journal of Neurology Neurosurgery & Psychiatry* 1996, 61(5):433-43
- 5 Trescher WH, Lesser RP. (1996) The Epilepsies. In: *Neurology in Clinical Practice, the Neurological Disorders, 2nd ed. Volume II.* Chapter 72. Pp. 1625-1654. Eds. Bradley WG, Daroff RB, Fenichel GM, Marsden CD : Butterworth-Heinemann
- 6 Wada JA, Wake A, Sato M, Corcoran ME. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. *Epilepsia* 1975, 16:503-10
- 7 Tanaka T, Naquet R. Kindling effect and sleep organization in cats. *Electroenceph Clin Neurophys.* 1975, 39:449-54
- 8 Sutula T, He XX, Cavazos J, Scott G. Synaptic reorganization in the hippocampus induced by abnormal functional activity. *Science* 1988, 239:1147-1150
- 9 Represa A, LeGall La Salle G, Ben-Ari Y. Hippocampal plasticity in the kindling model of epilepsy in rats. *Neurosci Lett* 1989, 99:345-350
- 10 Cavazos JE, Golarai G, Sutula TP. Mossy fiber sprouting reorganization induced by kindling: time course, development, progression and permanence. *J Neurosci* 1991, 11:2795-2803
- 11 Scott BW, Wang S, Burnham WM, Boni UD, Wojtowicz JM. Kindling-induced neurogenesis in the dentate gyrus of the rat. *Neuroscience Letters* 1998, 248:73-76

- 12 Dasheiff RM, Savage DD, McNamara JO. Seizures down-regulate muscarinic cholinergic receptors in hippocampal formation. *Brain Research* 1982, 235(2):327-34
- 13 Kraus JE, Nadler JV, McNamara JO. Regulation of alternative splicing of NMDAR1 in the kindling model. *Brain Research Molecular Brain Research* 1996, 41(1-2):97-104
- 14 Prince HK, Conn PJ, Blackstone CD, Huganir RL, Levey AI. Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. [Journal Article] *Journal of Neurochemistry*. 64(1):462-5, 1995
- 15 Cincotta M, Young NA, Beart PM. Unilateral up-regulation of glutamate receptors in limbic regions of amygdaloid-kindled rats. *Experimental Brain Research* 1991, 85(3):650-8
- 16 Jones SM, Johnson KM. Effects of amygdaloid kindling on NMDA receptor function and regulation. *Experimental Neurology* 1989, 106(1):52-60
- 17 Dragunow M, Robertson HA. Kindling stimulation induces c-fos protein(s) in granule cells of the rat dentate gyrus. *Nature* 1987, 329(6138):441-2
- 18 Hughes PE, Young D, Preston KM, Yan Q, Dragunow M. Differential regulation by MK801 of immediate-early genes, brain-derived neurotrophic factor and trk receptor mRNA induced by a kindling after-discharge. *Brain Research. Molecular Brain Research* 1998, 53(1-2):138-51
- 19 Elmer E, Kokaia M, Kokaia Z, Ferencz I, Lindvall O. Delayed kindling development after rapidly recurring seizures: relation to mossy fiber sprouting and neurotrophin, GAP-43 and dynorphin gene expression. *Brain Research* 1996, 712(1):19-34
- 20 Shin C, McNamara JO, Morgan JJ, Curran T, Cohen DR. Induction of c-fos mRNA expression by afterdischarge in the hippocampus of naïve and kindled rats. *J Neurochem* 1990, 55:1050-55
- 21 Simonato M, Molteni R, Bregola G, Muzzolini A, Piffanelli M, Beani L, Racagni G, Riva M. Different patterns of induction of FGF-2, FGF-1 and BDNF mRNAs during kindling epileptogenesis in the rat. *European Journal of Neuroscience* 1998, 10:955-63

- 22 Swanson TH. The pathophysiology of human mesial temporal lobe epilepsy. *Journal of clinical Neurophysiology* 1995, 12(1):2-12
- 23 Lothman EW, Hatlelid JM, Zorumski CF, Conry JA, Moon PF, Perlin JB. Kindling with rapidly recurring hippocampal seizures. *Brain Research* 1985, 360:83-91
- 24 Lothman EW, Williamson JM. Rapid kindling with recurrent hippocampal seizures. *Epilepsy Research* 1993, 14:209-220
- 25 Represa A, Ben-Ari Y. Kindling is associated with the formation of novel mossy fiber synapses in the CA3 region. *Exp. Brain Res.* 1992,92:69-78
- 26 Ebert U, Loscher W. differences in mossy fibre sprouting during conventional and rapid amygdala kindling of rat. *Neurosci Lett* 1995, 190:199-202
- 27 Jonec V, Walsterlain CG. Effect of inhibitors of protein synthesis on the development of kindled seizures in rats. *Experimental Neurology* 1979, 66(3):524-32
- 28 Teskey GC, Atkinson BG, Cain DP. Expression of the proto-oncogene c-fos following electrical kindling in the rat. *Brain Res Mol Brain Res* 1991, 11:1-10
- 29 Simonato M, Hosford DA, Labiner DM, Shin C, Mansbach HH, McNamara JO. Differential expression of immediate early genes in the hippocampus in the kindling model of epilepsy. *Brain Res Mol Brain Res* 1991, 11:115-124
- 30 Chiasson BJ, Dennison Z, Robertson HA. Amygdala kindling and immediate-early genes. *Brain Res Mol Brain Res* 1995, 29
- 31 Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. *Nature* 1993, 361:453-7
- 32 Enfors P, Bengzon J, KoKaia Z, Persson H, Lindvall O. Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. *Neuron* 1991,7:165-76
- 33 Bengzon J, Kokaia Z, Ernfors P, Kokaia M, Leanza G, Nilsson OG, Persson H, Lindvall O. Regulation fo neurotrophin and trkA, trkB and trkC tyrosine kinase receptor messenger RNA expression in kindling. *Neuroscience* 1993, 53:433-446

- 34 Clark M, Smith MA, Weiss SRG, Post RM. Modulation of hippocampal glucocorticoid and mineralocorticoid receptor mRNA expression by amygdaloid kindling. *Neuroendocrinology* 1994, 59:451-56
- 35 Bronstein JM, Micevych P, Propper P, Huez G, Farber DB, Wasterlain CG. Long-lasting decrease of type II calmodulin kinase expression in kindled rat brains. *Brain Res* 1992, 584:257-60
- 36 Kamphuis W, Hendriksen H, Diegenbach PC and Lopes da Silva FH. N-methyl-D-aspartate and kainate receptor gene expression in hippocampal pyramidal and granular neurons in the kindling model of epileptogenesis. *Neuroscience* 1995, 67(3):551-9
- 37 Hikiji M, Tomita H, Ono M, Fujiwara Y, akiyama K. Increase of kainate receptor mRNA in the hippocampal CA3 of amygdala-kindled rats detected by in situ hybridization. *Life Sci* 1993, 3:857-64
- 38 Kamphuis W, De Rijk TC, Talamini LM, Lopes da Silva FH. Rat hippocampal kindling induces changes in glutamate receptor mRNA expression patterns in dentate granule neurons. *Eur J Neurosci* 1994, 6:1119-1127
- 39 Clark M, Massenburg GS, Weiss SR, Post RM, Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine. *Brain Research Molecular Brain Research* 1994, 26(1-2):309-19
- 40 Kokaia M, Pratt GD, Elmer E, Bengzon J, Fritschy JM, Kokaia Z, Lindvall O, Mohler H. Biphasic differential changes of GABAA receptor subunit mRNA levels in dentate gyrus granule cells following recurrent kindling-induced seizures. *Brain Research. Molecular Brain Research* 1994, 23(4):323-32
- 41 Kamphuis W, De Rijk TC, Lopes da Silva FH. GABAA receptor beta 1-3 subunit gene expression in the hippocampus of kindled rats. *Neuroscience Letters*. 1994, 174(1):5-8
- 42 Burazin TC, Gundlach AL. Rapid and transient increases in cellular immediate early gene and neuropeptide mRNAs in cortical and limbic areas after amygdaloid kindling seizures in the rat. *Epilepsy Research* 1996, 26(1):281-93

- 43 Harrison MB, Shumate MD, Lothman EW. Opioid peptide expression in models of chronic temporal lobe epilepsy. *Neuroscience* 1995, 65(3):785-95
- 44 Moneta ME, Holtt V. Perforant path kindling induces differential alterations in the mRNA levels coding for prodynorphin and proenkephalin in the rat hippocampus. *Neuroscience Letters* 1990, 110(3):273-8
- 45 Xie CW, Lee PH, Douglass J, Crain B, Hong JS. Deep prepyriform cortex kindling differentially alters the levels of prodynorphin mRNA in rat hippocampus and striatum. *Brain Research* 1989, 495(1):156-60
- 46 Greenwood RS, Abdou A, Meeker RB, Hayward JN. Vasopressin mRNA changes during kindling: the effects of kindling site and stage. *Brain Research. Molecular Brain Research* 1994, 26(1-2):286-92
- 47 Greenwood RS, Meeker RB, Abdou A, Hayward JN. Kindled seizures induce a long-term increase in vasopressin mRNA. *Brain Research. Molecular Brain Research* 1994, 24(1-4):20-6
- 48 Perlin JB, Gerwin CM, Panchision DM, Vick RS, Jakoi ER, DeLorenzo RJ. Kindling produces long-lasting and selective changes in gene expression of hippocampal neurons. *Proceedings of the National Academy of Sciences of the United States of America* 1993, 90(5):1741-5
- 49 McNamara JO. Analyses of the molecular basis of kindling development. [Review] *Psychiatry & Clinical Neurosciences* 1995, 49(3):S175-8
- 50 Sutula TP, Golarai G, Cavazos J. Assessing the functional significance of mossy fiber sprouting. [Review] *Epilepsy Research - Supplement* 1992, 7:251-9
- 51 Bengzon J, Kokaia Z, Elmer E, Nanobashvili A, Kokaia M, Lindvall O. Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures. *Proceedings of the National Academy of Sciences of the United States of America* 1997, 94(19):10432-7
- 52 Pretel S, Applegate CD, Piekut D. Apoptotic and necrotic cell death following kindling induced seizures. *Acta Histochemica* 1997, 99(1):71-9
- 53 Benveniste J. Passage of immune complexes through vascular walls. Evidence for the role of an immediate hypersensitivity mechanism and its mediator: platelet-activating factor. *Rheumatology* 1975, 6:293-302

- 54 Kulikov VI, Muzya GI. The bioregulatory role of platelet-activating factor in intracellular processes and cell-cell interactions. [Review] *Biochemistry* 1998, 63(1):47-54
- 55 Yamada Y, Yokota M. Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory, and atherosclerotic diseases. [Review] *Japanese Circulation Journal* 1998, 62(5):328-35
- 56 Frenkel RA, Muguruma K, Johnston JM. The biochemical role of platelet-activating factor in reproduction. [Review] *Progress in Lipid Research* 1996, 35(2):155-68
- 57 Toyoshima K, Narahara H, Furukawa M, Frenkel RA, Johnston JM. Platelet-activating factor. Role in fetal lung development and relationship to normal and premature labor. [Review] *Clinics in Perinatology* 1995, 22(2):263-80
- 58 Alecozay AA, Casslen BG, Riehl RM, DeLeon FD, Harper MJK, Silva M, Nouchi TA, Hanahan DJ. Platelet-activating factor in human luteal phase endometrium. *Biol Reprod* 1989, 41:578
- 59 Tokumura A, Kamiyasu K, Takanchi K, Tsukatani H. Evidence for the existence of various homologues and analogues of platelet activating factor in a lipid extract from bovine brain. *Biochem Biophys. Res Commun* 1987, 145:415-25
- 60 Kumar R, Harvey SA, Kester M, Hanahan DJ, Olson MS. Production and effects of platelet-activating factor in the rat brain. *Biochimica et Biophysica Acta* 1988, 963(2):375-83
- 61 Yue TL, Lysko PG, Feuerstein G. Production of platelet-activating factor from rat cerebellar granule cells in culture. [Journal Article] *Journal of Neurochemistry*. 54(5):1809-11, 1990
- 62 Sogos V, Bussolino F, Pilia E, Torelli S, Gremo F. Acetylcholine-induced production of platelet-activating factor by human fetal brain cells in culture. *Journal of Neuroscience Research* 1990, 27(4):706-11
- 63 Kornecki E, Wieraszko A, Chan J, Ehrlich YH. Platelet activating factor (PAF) in memory formation: role as a retrograde messenger in long-term potentiation. *Journal of Lipid Mediators & Cell Signalling* 1996, 14(1-3):115-26

- 64 Bazan NG, Allan G. Platelet-activating factor in the modulation of excitatory amino acid neurotransmitter release and of gene expression. [Review] *Journal of Lipid Mediators & Cell Signalling* 1996, 14(1-3):321-30
- 65 Gotz E, Olenik C, Uhl A, Seregi A, Meyer DK. Meningocortical lesion increases expression of the cholecystokinin gene in rat cerebral cortex: evidence for the involvement of platelet-activating factor (PAF). *Molecular Brain Research* 1993, 18(4):285-9
- 66 Ye RD, Kravchenko VV, Pan Z, Feng L. Stimulation of NF-kappa B activation and gene expression by platelet-activating factor. [Review] *Advances in Experimental Medicine & Biology* 1996, 416:143-51
- 67 DeCoster MA, Mukherjee PK, Davis RJ, Bazan NG. Platelet-activating factor is a downstream messenger of kainate-induced activation of mitogen-activated protein kinases in primary hippocampal neurons. *Journal of Neuroscience Research* 1998, 53(3):297-303
- 68 Honda Z, Takano T, Gotoh Y, Nishida E, Ito K, Shimizu T. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. *Journal of Biological Chemistry* 1994, 269(3):2307-15
- 69 Tabuchi S, Kume K, Aihara M, Ishii S, Mishina M, Shimizu T. Lipid mediators modulate NMDA receptor currents in a *Xenopus* oocyte expression system. *Neuroscience Letters* 1997, 237(1):13-6
- 70 Bazan NG, Rodriguez de Turco EB, Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. [Review] *Journal of Neurotrauma* 1995, 12(5):791-814
- 71 O'Neill LA, Kaltschmidt C, NF-kappa B. a crucial transcription factor for glial and neuronal cell function [see comments]. [Review] *Trends in Neurosciences* 1997, 20(6):252-8
- 72 Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. [Review] *Current Opinion in Immunology* 1996, 8(3):402-11
- 73 Gilbert ME. The NMDA-receptor antagonist, MK-801, suppresses limbic kindling and kindled seizures. *Brain Research* 1988, 463(1):90-9

- 74 Croucher MJ, Bradford HF. Kindling of full limbic seizures by repeated microinjections of excitatory amino acids into the rat amygdala. *Brain Research* 1989, 501(1):58-65
- 75 Trommer BL, Pasternak JF. NMDA receptor antagonists inhibit kindling epileptogenesis and seizure expression in developing rats. *Brain Research. Developmental Brain Research* 1990, 53(2):248-52
- 76 Holmes KH, Bilkey DK, Laverty R, Goddard GV. The N-methyl-D-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures. *Brain Research* 1990, 506(2):227-35
- 77 Croucher MJ, Bradford HF. NMDA receptor blockade inhibits glutamate-induced kindling of the rat amygdala. *Brain Research* 1990, 506(2):349-52
- 78 Hirayasu Y, Wada JA. N-methyl-D-aspartate injection into the massa intermedia facilitates development of limbic kindling in rats. *Epilepsia* 1992, 33(6):965-70
- 79 Croucher MJ, Cotterell KL, Bradford HF. Competitive NMDA receptor antagonists raise electrically kindled generalized seizure thresholds. *Neurochemical Research* 1992, 17(5):409-13
- 80 Kohr G, De Koninck Y, Mody I. Properties of NMDA receptor channels in neurons acutely isolated from epileptic (kindled) rats. *Journal of Neuroscience* 1993, 13(8):3612-27
- 81 Croucher MJ, Cotterell KL, Bradford HF. Amygdaloid kindling by repeated focal N-methyl-D-aspartate administration: comparison with electrical kindling. *European Journal of Pharmacology* 1995, 286(3):265-71
- 82 Loscher W. Pharmacology of glutamate receptor antagonist in the kindling model of epilepsy. *Progress in Neurobiology* 1998, 54:721-741
- 83 Sutula T, Koch J, Golarai G, Watanabe Y, McNamara JO. NMDA receptor dependence of kindling and mossy fiber sprouting: evidence that the NMDA receptor regulates patterning of hippocampal circuits in the adult brain. *Journal of Neuroscience* 1996, 16(22):7398-406


- 84 Bazan NG, Packard MG, Teather L, Allan G. Bioactive lipids in excitatory neurotransmission and neuronal plasticity. [Review] *Neurochemistry International*. 1997, 30(2):225-31
- 85 Bito H, Nakamura M, Honda Z, Izumi T, Iwatsubo T, Seyama Y, Ogura A, Kudo Y, Shimizu T. Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca^{2+} in hippocampal neurons. *Neuron* 1992 , 9(2):285-94
- 86 Shi LC, Wang HY, Friedman E. Involvement of platelet-activating factor in cell death induced under ischemia/postischemia-like conditions in an immortalized hippocampal cell line. *Journal of Neurochemistry* 1998, 70(3):1035-44
- 87 Francescangeli E, Lang D, Dreyfus H, Boila A, Freysz L, Goracci G. Activities of enzymes involved in the metabolism of platelet-activating factor in neural cell cultures during proliferation and differentiation. *Neurochemical Research* 1997, 22(10):1299-307
- 88 Francescangeli E, Domanska-Janik K, Goracci G. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. *Journal of Lipid Mediators & Cell Signalling* 1996, 14(1-3):89-98
- 89 Bonventre JV. Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity [corrected and republished article originally printed in *J Lipid Mediat Cell Signal* 1996 Sep; 14(1-3):15-23]. *Journal of Lipid Mediators & Cell Signalling* 1997, 17(1):71-9
- 90 Marcheselli VL, Rossowska MJ, Domingo MT, Braquet P, Bazan NG. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. *Journal of Biological Chemistry* 1990, 265(16):9140-5
- 91 Honda Z, Nakamura M, Seyama Y, Shimizu T. Properties of the guinea-pig lung platelet-activating factor receptor encoded by the cloned cDNA. *Journal of Lipid Mediators* 1992, 5(2):105-7
- 92 Bito H, Honda Z, Nakamura M, Shimizu T. Cloning, expression and tissue distribution of rat platelet-activating-factor-receptor cDNA. *European Journal of Biochemistry* 1994, 221(1):211-8

- 93 Kunz D, Gerard NP, Gerard C. The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. *Journal of Biological Chemistry* 1992, 267(13):9101-6
- 94 Sugimoto T, Tsuchimochi H, McGregor CG, Mutoh H, Shimizu T, Kurachi Y. Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart. *Biochemical & Biophysical Research Communications* 1992, 189(2):617-24
- 95 Marcheselli VL, Bazan NG. Platelet-activating factor is a messenger in the electroconvulsive shock-induced transcriptional activation of c-fos and zif-268 in hippocampus. *Journal of Neuroscience Research* 1994, 37(1):54-61
- 96 Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* 1998, 38:97-120
- 97 Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. *Proc Soc Exp Biol Med* 1997, 216(2):201-10
- 98 Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stetler RA, Isakson PC, Chen J, Graham SH. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. *Proc Natl Acad Sci U S A* 1998, 95(18):10954-9
- 99 Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. *Exp Neurol* 1997, 144(2):339-49
- 100 Ho L, Osaka H, Aisen PS, Pasinetti GM. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. *J Neuroimmunol* 1998, 89(1-2):142-9
- 101 Marcheselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. *J Biol Chem* 1996, 271(40):24794-9

Figure 1


A

Hypothesis



B

Before Kindling



After Kindling





Figure 2

A



Stimulation delivered and after discharge monitored

B




Figure 3

Kindling Protocol

- 9 days of stimulation every other day.
- 12 daily stimulations every 1/2 hour.
- Each stimulation contains one train of 50 Hz pulses, lasting 10 seconds.
- Each pulse consists of one biphasic square wave pulse, lasting for 2 milliseconds.
- The intensity of stimulation was kept constant at 400 μ A




Figure 4





Figure 5

A



B





Figure 6

A



B





Figure 7

A



B






Figure 8

A



B



Pretreatment of animals with the intracellular PAF antagonist BN 50730 strongly attenuates COX-2 induction by kainic acid. We are currently testing the hypothesis that the overexpression of the PAF-COX-2 pathway leads to neuronal cell apoptosis in several CNS disease models. Although it is often stated that the inflammatory response is not associated with apoptotic cell death, PAF and COX-2 appear to act as neuron injury messengers without reflecting classical "inflammatory" features to the entire tissue.

Key words: COX-2, PAF, kainic acid, apoptosis, hippocampus, gene expression, neuroprotection

Introduction

Neuronal and glial cell membranes store a wide variety of lipid messengers as part of phospholipid molecules. Receptor-mediated events and changes in intracellular $[Ca^{2+}]$, which occur during excitatory neurotransmission and in activity-dependent synaptic plasticity, activate phospholipases that catalyze the release of bioactive moieties from membrane phospholipid. These messengers then participate in intracellular and/or intercellular signaling pathways. Bioactive lipids have significant neurobiological actions in neurotransmitter release, synaptic plasticity, and programs of neuronal gene expression. Accordingly, much of contemporary research into bioactive lipids has focussed on their neurobiological significance.

Stroke, neurotrauma, epileptic brain damage and, likely, neurodegenerative diseases (e.g., Alzheimer's) disrupt the tightly regulated enzymes that control the production and accumulation of lipid messengers, such as free arachidonic acid, diacylglycerol, and platelet-activating factor, (PAF, 1-0-alkyl-2-acyl-sn-3-phosphocholine), under physiological conditions. Rapid activation of phospholipases, particularly of phospholipase A_2 (PLA₂), occurs at the onset of cerebral ischemia and seizures (Bazan, Rodriguez de Turco, and Allan, 1995). There are a wide variety of PLA₂s (Dennis, 1994), and current investigations aim to define those affected by different pathological conditions. For example, in addition to the role(s) of intracellular PLA₂s in lipid messenger formation, it has recently been discovered that a low molecular weight, secretory PLA₂ synergizes glutamate-induced neuronal damage (Kolko, DeCoster, Rodriguez de Turco, 1996). Therefore, a synaptic secretory PLA₂ may also be a target in these diseases. Whereas pathways leading to PLA₂ activation/release are part of normal neuronal function, ischemia-reperfusion and other pathological conditions enhance these events, overproducing PLA₂-derived lipid messengers involved in neuronal damage (e.g., enzymatically produced arachidonic acid oxygenation

metabolites, non-enzymatically generated lipid peroxidation products, and other reactive oxygen species, PAF). For example, among the consequences of PLA₂ activation by ischemia are alterations in mitochondrial function by the rapid increase in the brain free fatty acid pool size that leads to the uncoupling of oxidative phosphorylation from respiratory chain. The major consequence is the pathological accumulation of lipid messengers.

PAF is a very potent and short-lived lipid messenger. It is known to have a wide range of actions: as a mediator of inflammatory and immune responses, as a second messenger, and as a potent inducer of gene expression in neural systems. Thus, in addition to its acute roles, PAF can potentially mediate longer-term effects on cellular physiology and brain functions. Furthermore, the early response gene, prostaglandin endoperoxide synthase-2 (PGS-2, COX-2, TIS-10), performs a dual function similar to PAF. Prostaglandin G/H synthase-2 catalyzes the cyclooxygenation and peroxidation of arachidonic acid into PGH₂, the precursor of biologically active prostaglandins, thromboxanes, and prostacyclin. PGS-1 also catalyzes the same first committed step of the arachidonic acid cascade. PGS-2, however, is expressed in response to mitogenic and inflammatory stimuli. In contrast, PGS-1 expression is not subject to short-term regulation. Neurons in the hippocampus, as well as in a few other brain regions, are unlike other cells in that they display basal levels of PGS-2 expression (Yamagata *et al.*, 1993). This expression is modulated by synaptic activity, LTP and involves the N-methyl-D-aspartate class of glutamate receptors (Yamagata *et al.*, 1993; Kaufmann *et al.*, 1996). In pathological environments present in seizures, ischemia, and neurodegenerative diseases such as Alzheimer's disease, an increased expression of PGS-2 is observed. Additionally, since PAF is a transcriptional activator of PGS-2 (Bazan *et al.*, 1994), both may be linked as a signaling system in neuronal responses to synaptic activation and in CNS diseases. Moreover, PGS-2 is expressed in neurons (Yamagata *et al.*, 1993), and PAF elicits neuronal plasticity actions (Shimizu and Wolfe, 1990; Clark *et al.*, 1992; Kato *et al.*, 1994). This chapter discusses the significance of PAF and PGS-2 as inflammatory mediators in the CNS.

PAF Modulates Synaptic Plasticity, and in Pathological Conditions, Contributes to Excitotoxicity by Enhancing Glutamate Release

PAF enhances glutamate release in synaptically-paired rat hippocampal neurons in culture (Clark *et al.*, 1992). The PAF analogue methylcarbamil (mc-PAF), but not biologically inactive lyso PAF, increases excitatory synaptic responses. The inhibitory neurotransmitter γ -aminobutyric acid is unaffected by mc-PAF under these conditions. The presynaptic PAF receptor

antagonist BN-52021 blocks the mc-PAF-enhanced glutamate release. In addition, mc-PAF increases presynaptic glutamate release, since it does not augment the effects of exogenously added glutamate, and it evokes spontaneous synaptic responses characteristic of enhanced neurotransmitter release. Therefore, as a modulator of glutamate release, PAF participates in long-term potentiation (Kato *et al.*, 1994), synaptic plasticity, and memory formation.

Ischemia and seizures increase PAF content in brain (for reference see Bazan, Rodriguez de Turco, and Allan, 1995). Furthermore, brain is endowed with a variety of degradative enzymes that rapidly convert PAF to biologically inactive lyso PAF (Bazan, 1995). Presynaptic membranes display PAF binding that can be displaced by BN-52021, a terpenoid extracted from the leaf of the *Ginkgo biloba* tree, which binds preferentially to the synaptosomal site (Marcheselli *et al.*, 1990). It is likely that this PAF binding site is the seven transmembrane PAF receptor that has been cloned (Bazan, Rodriguez de Turco, and Allan, 1995). BN-52021 inhibits both PAF-induced glutamate release (Yamagata *et al.*, 1993) and long-term potentiation (Kato *et al.*, 1994). Moreover, this antagonist is neuroprotective in ischemia-reperfusion damage in the gerbil brain (for reference see Bazan, Rodriguez de Turco, and Allan, 1995). Taking these findings together, PAF, when overproduced at the synapse during ischemia, will promote enhanced glutamate release that in turn, through the activation of post-synaptic receptors, will contribute to excitotoxicity.

PAF is a Transcriptional Activator of Prostaglandin Endoperoxide Synthase-2

In addition to its modulatory effect on synaptic transmission and neural plasticity, PAF activates receptor-mediated immediate early gene expression (Squinto *et al.*, 1989; 1990; Bazan *et al.*, 1991). Since PAF is a phospholipid and can pass through membranes, it is rapidly taken up by cells. An intracellular binding site with very high affinity, yet pharmacologically distinct from the presynaptic site, was found in brain (Marcheselli *et al.*, 1990). The synthetic hexazepine BN-50730 is selective for this intracellular site and blocks PAF-induced gene expression of PGS-2 in transfected cells (Bazan *et al.*, 1994).

PAF is a transcriptional activator of PGS-2, as PAF induces mouse PGS-2 promoter-driven luciferase activity transfected in neuroblastoma cells (NG108-15 or SH-SY5Y) and in NIH 3T3 cells. The intracellular PAF antagonist, BN-50730, inhibits PAF activation of this construct (Bazan *et al.*, 1994). Figure 11.1 outlines the role of PAF as a presynaptic messenger.




Figure 11.1. Inhibition by BN-50730 of KA-induced PGS-2 mRNA (open bars) and *zif*-268 mRNA (closed bars) accumulation in rat hippocampus and cerebral cortex. Animals were pretreated intracerebroventricularly with BN-50730 in DMSO (experimental) or DMSO alone (control) 15 min before KA injection. RNA was extracted for Northern blot analysis 2 hr after KA injection ($n=6$ from two separate experiments, error bars ± 1 s.d.). (Published with permission from Marcheselli and Bazan (1996) in *Journal of Biological Chemistry*, 271.)

Sustained Transcriptional Upregulation of PGS-2 Precedes Kainic Acid-Induced Neuronal Damage in Hippocampus

The abundance in brain of several early-response gene transcripts shows rapid and transient increases during cerebral ischemia and after seizures (Morgan and Curran, 1991a; Marcheselli and Bazan). Several early-response genes encode transcription factors that in turn modulate the expression of other genes, whereas others encode inducible enzymes. The glutamate analogue, kainic acid, promotes extensive neuronal damage, particularly in the hippocampus (Pollard *et al.*, 1994), and also induces early-response genes such as the transcription factor *zif*-268 (Marcheselli and Bazan, 1994). PGS-2 is also induced under these conditions, but there are striking

differences in the magnitude and duration of the induction of PGS-2 as compared with *zif*-268. The PGS-2 peak in mRNA abundance was evident at 3 hr (71-fold increase) as compared to 1 hr for *zif*-268 (10-fold increase). *Zif*-268 mRNA time-course of changes in the hippocampus corresponds to the expected profile of early-response genes; i.e., a rapid decrease in abundance after the peak is apparent. PGS-2, on the other hand, displayed sustained upregulation for several hours after kainic acid injection (5.2 fold increase at 12 hr) (Marcheselli and Bazan, 1996). The increased PGS-2 mRNA abundance in hippocampus after kainic acid may be due to enhanced transcription, increased availability of factors that prolong mRNA half-life (e.g., PGS-2 mRNA binding proteins), and/or changes in translational modulation. Therefore, to assess if transcriptional activation is involved in PGS-2 and *zif*-268 induced expression by kainic acid nuclear run-on, transcription assays were conducted. The pattern of transcriptional activation qualitatively matched the profile of changes in mRNA abundance (Figure 11.2B). The level of relative stimulation of PGS-2 transcription was, however, less than the relative increases in mRNA. It should be noted that the methodologies used to obtain these two sets of values differ in several aspects and may not be readily comparable. As a consequence, *in vitro* transcription patterns are to be considered as analogous to mRNA abundance (Marcheselli and Bazan, 1996). Analogous, comparative patterns are also displayed in Figure 11.2A and 11.2B between *in vitro* transcription and mRNA abundance for *zif*-268. The transcriptional activation of PGS-1, as depicted in Figure 11.2B, displayed no induction up to 6 hr; however, there was a small increase after 72 hr of kainic acid treatment.

PGS-2 expression, as analyzed 2 hr after kainic acid injection, was highest in hippocampus (35-fold), followed by cerebral cortex (8-fold) (Figure 11.1). While small increases were observed in brain stem and striatum, there were no changes in cerebellum. The largest induction of *zif*-268 was also observed in hippocampus (5.5-fold) followed by cerebral cortex (4.8-fold). Again, the changes observed in brain stem and striatum were small, with no detectable changes in cerebellum (Figure 11.1). The intracellular PAF receptor antagonist BN-50730 given intracerebro-ventricularly (icv) 15 min prior to kainic acid administration reduces both PGS-2 mRNA (data not shown) and protein (Figure 11.3). Under the same conditions, PGS-1 protein was not affected.

The Platelet Activating Factor-Prostaglandin G/H Synthase-2 Intracellular Signaling Pathway and Apoptosis

A PAF-stimulated signal transduction pathway is a major component of the kainic acid-induced PGS-2 expression in hippocampus. This conclusion is




Figure 11.2. Time course of changes in relative mRNA abundance and transcriptional activity in hippocampus after KA treatment or a single electroconvulsive shock (ECS). (A) Relative abundance of PGS-2 and *zif-268* mRNAs compared to GAPDH mRNA, as assessed by northern analysis ($n=9-12$ for each time point from 3 separate experiments, error bars ± 1 s.d.) (B) Transcriptional activity of PGS-2, PGS-1, and *zif-268* genes assessed by nuclear run-on transcription ($n=3-4$ from three separate experiments). Data are normalized to transcriptional activity of GAPDH. (Published with permission from Marcheselli and Bazan (1996) in *Journal of Biological Chemistry*, 271.)

based upon the finding that (a) PAF induces mouse PGS-2 promoter-driven luciferase activity in transfected cells, and BN-50730 inhibits this effect (Bazan *et al.*, 1994); and (b) BN-50730 inhibits kainic acid-induced PGS-2 mRNA and protein accumulation in hippocampus by 90% (Bazan *et al.*, 1994). Both PAF (Prescott, Zimmerman, and McIntyre, 1990) and PGS-2 (Bazan, Botting, and Vane, 1996) are potent mediators of the injury/inflammatory response (Clark *et al.*, 1992; Kato *et al.*, 1994). PAF and PGS-2 (Yamagata *et al.*, 1993; Kaufmann *et al.*, 1996) are also interrelated in neuronal plasticity. The PAF transcriptional activation of PGS-2 may provide clues about novel neuronal cell death pathways. The antagonist




Figure 11.3. Inhibition by BN-50730 pretreatment of KA-induced PGS-2 protein accumulation (open bars), but not of endogenous PGS-1 (closed bars) in rat hippocampus. (A) Representative Western blots. BN-50730 or vehicle treatments were as for Figure 11.4. Samples were collected 6 hr after KA treatment. (B) Quantification of Western blot data expressed as a percent increase over control (vehicle-pretreated) values ($n=10-12$ from three separate experiments, error bars ± 1 s.d.). (Published with permission from Marschelli and Bazan (1996) in *Journal of Biological Chemistry*, 271.)

BN-50730 was much less effective against *zif*-268 expression (Figure 11.4). In fact, the delayed hippocampal induction of PGS-2 by kainic acid precedes selective neuronal apoptosis by this agonist in this neuroanatomical region (Pollard *et al.*, 1994).




Figure 11.4. Excitatory synaptic transmission enhances the production of PAF, other messengers, and the expression of PGS-2. NMDA-receptor activation by glutamate leads to phospholipase A₂ activation and the generation of PAF and arachidonic acid. PAF is synthesized through other metabolic routes as well (10). Other synaptic events, in addition to NMDA-receptor, may also be involved in the accumulation of PAF. PAF activates PGS-2 gene expression through a BN-50730-sensitive intracellular site, protein kinase cascades, and transcription factors. The PGS-2 promoter is also a target for cytokines (activation) and glucocorticoids (inhibition). PGS-2 protein (COX-2) then catalyzes the conversion of arachidonic acid into PGH₂, the precursor of eicosanoids. Constitutive PGS-1 also catalyzes this metabolic step (not shown). Prostaglandin E₂ is depicted as a product of PGS-2 (COX-2). The specific products of overexpressed PGS-2 are not yet known. PGE₂ is shown to potentially elicit genomic, paracrine, and/or autocrine effects.

In neurotrauma, cerebrovascular and neurodegenerative diseases, the significance of the PLA₂-related signaling triggered by ischemia reperfusion may be part of events that are finely balanced between neuroprotection and neuronal cell death. The precise events that would tilt this balance toward the latter are currently being investigated. We are exploring the hypothesis that PAF-COX-2 is a common signaling pathway involved in neurodegenerative diseases as diverse as retinitis pigmentosa and Alzheimer's Disease. It is interesting to note that PAF, being short-lived and rapidly degraded by PAF acetylhydrolase (Bazan, 1995; Tjoelker *et al.*, 1995), behaves as a long-term signal with consequences to neurons through PGS-2 sustained expression. It is also interesting that the PAF-PGS-2 pathway may be activated in neurons as an early event in the pathophysiology of several diseases, and although this pathway is a component of the "classical inflammatory" response, it is restricted to a disruption of intracellular signaling. In fact, apoptosis, by definition, lacks an initial inflammatory component. PGS-2 is localized in the nuclear envelope and perinuclear endoplasmic reticulum. The overexpression of hippocampal PGS-2 during cerebral ischemia and seizures may lead, in turn, to the formation of neurotoxic metabolites (e.g., superoxide). Current investigations are attempting to determine whether other messengers cooperate to enhance neuronal damage (e.g., nitric oxide), as well as examining the possible involvement of astrocytes and microglial cells. Further understanding of these potentially neurotoxic events involving lipid messengers and PGS-2 will permit the identification of new strategies and define therapeutic windows for the management of the inflammatory component in stroke, epileptic brain damage, head injury, and neurodegenerative diseases.

Acknowledgments

This work was supported by NIH grant NS23002 and DAMD 17-93-V-3013.

References

- Bazan, N.G., Botting, J., Vane, J.R. (Eds), (1996). *New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules*. William Harvey Press and Kluwer Academic Publishers, United Kingdom.
- Bazan, N.G. (1995). Inflammation: A signal terminator. *Nature*, **374**, 501-502.
- Bazan, N.G., Rodriguez de Turco, E.B. and Allan, G. (1995). Mediators of injury in neurotrauma: Intracellular signal transduction and gene expression. *J. Neurotrauma*, **12**, 789-911.

- Bazan, N.G., Fletcher, B.S., Herschman, H.R. and Mukherjee, P.K. (1994). Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. *Proc. Nat. Acad. Sci.*, **91**, 5252–5256.
- Bazan, N.G., Squinto, S.P., Braquet, P., Panetta, T. and Marcheselli, V.L. (1991). Platelet-activating factor and polyunsaturated fatty acids in cerebral ischemia or convulsions: Intracellular PAF-binding sites and activation of a Fos/Jun/AP-1 transcriptional signaling system. *Lipids*, **26**, 1236–1242.
- Clark, G.D., Happel, L.T., Zorumski, C.F. and Bazan, N.G. (1992). Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. *Neuron*, **9**, 1211–1216.
- Dennis, E.A. (1994). Diversity of group types, regulation and function of phospholipase A₂. *J. Biol. Chem.*, **269**, 13057–13060.
- Kato, K., Clark, G.D., Bazan, N.G. and Zorumski, C.F. (1994). Platelet activating factor as a potential retrograde messenger in Ca¹ hippocampal long-term potentiation. *Nature*, **367**, 175–179.
- Kaufmann, W.E., Worley, P.F., Pegg, J., Bremer, M. and Isakson, P. (1996). COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. *Proc. Nat. Acad. Sci.*, **93**, 2317–2321.
- Kolko, M., DeCoster, M.A., Rodriguez de Turco, E.B. and Bazan, N.G. (1997). Synergy by secretory phospholipase A₂ and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. *J. Biol. Chem.*, **271**, 32722–32728 (1996).
- Marcheselli, V.L. and Bazan, N.G. (1996). Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. *J. Biol. Chem.*, **271**, 24794–24799.
- Marcheselli, V.L. and Bazan, N.G. (1994). Platelet-Activating Factor Is a Messenger in the Electroconvulsive Shock-Induced Transcriptional Activation of *c-fos* and *zif-268* in Hippocampus. *J. Neurosci. Res.*, **37**, 54–61.
- Marcheselli, V.L., Rossowska, M., Domingo, M.T., Braquet, P. and Bazan, N.G. (1990). Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. *J. Biol. Chem.*, **265**, 9140–9145.
- Morgan, J.L. and Curran, T. (1991a). Proto-oncogene transcription factors and epilepsy. *TIPS*, **12**, 343–349.
- Pollard, H., Charriaut-Marlangue, C., Cantagral, S., Repress, A., Robain, O., Moreau, J. and Ben-Ari, Y. (1994). Kainate-induced apoptotic cell death in hippocampus. *Neuroscience*, **63**, 7–18.
- Prescott, S.M., Zimmerman, G.A. and McIntyre, T.M. (1990). Platelet-activating factor. *J. Biol. Chem.*, **265**, 17381–17384.
- Shimizu T. and Wolfe, L.S. (1990). Arachidonic acid cascade and signal transduction. *J. Neurochem.*, **55**, 1–15.
- Squinto, S.P., Block, A.L., Braquet, P. and Bazan, N.G. (1990). Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T-lymphocytes. *J. Mol. Neuro.*, **2**, 79–84.
- Squinto, S.P., Block, A.L., Braquet, N.G. and Bazan, P. (1989). Platelet-activating factor stimulates a Fos/Jun/AP-1 transcriptional signaling system in human neuroblastoma cells. *J. Neurosci. Res.*, **24**, 558–566.
- Tjoelker, L.W., Eberhardt, C., Unger, J., Trong, H.L., Zimmerman, G.A., McIntyre, T.M., Stafforini, D.M., Prescott, S.M. and Gray, P.W. (1995). Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A₂ with a catalytic triad. *J. Biol. Chem.*, **270**, 25481–25487.
- Yamagata, K., Andreasson, K.I., Kaufmann, W.E., Barnes, P.F. and Worley, C.A. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. *Neuron*, **11**, 371–386.

Chapter 44, Second Messengers, Long-Term Potentiation, Gene Expression and Epileptogenesis in Basic Mechanisms of the Epilepsies, Second Edition, (Advances in Neurology) edited by A. Delgado-Escueta, W. Wilson, R. Olsen and R. Porter, Lippincott-Raven Publishers, New York, 1998.

Second Messengers, Long-Term Potentiation, Gene Expression and Epileptogenesis

Nicolas G. Bazan and Michael J. Serou

*Louisiana State University Medical Center,
School of Medicine, Neuroscience Center of Excellence
New Orleans, Louisiana*

Address correspondence to: Nicolas G. Bazan, Neuroscience Center of Excellence, Louisiana State University Medical Center School of Medicine, 2020 Gravier Street, Suite B, New Orleans, Louisiana 70112

Phone: 504-599-0832

FAX: 504-568-5801

E-mail: nbazan@lsu-mc.edu

Running title: Second messengers, LTP, genes and epileptogenesis

Introduction

Various forms of brain damage triggers cellular and molecular events that often result in impaired synaptic plasticity that, in turn, induces recurrent seizures and epileptic discharges in the electroencephalogram. Hippocampal sclerosis, frequently the result of early neurotrauma or other forms of brain damage, is thought to be a significant event in epileptogenesis. Our hypothesis is that epileptogenesis involves a synaptic signaling dysfunction engaging lipid messengers, some of which modulate cell function. Synaptic messengers participate in synaptic strengthening, known also as long-term potentiation (LTP), a cellular form of memory formation. The persistence of changes in LTP indicates that synaptic plasticity has taken place and suggests that signal transduction includes modulation of gene expression. In fact, LTP induces several early response genes, including transcription factors, which, in turn, regulate the expression of gene cascades as well as of genes that encode proteins which participate in other functions such as extracellular matrix development and remodeling. Therefore perturbing synaptic signaling may contribute to aberrant synaptic plasticity and epileptogenesis. Once that abnormal connections are established, enhanced excitability promotes and contributes to seizure development and propagation. As a consequence, further seizures trigger additional damage. This vicious cycle of events in epileptogenesis has received experimental support (e.g., 1-6).

Phospholipases A₂, Arachidonic Acid and PAF

Phospholipid molecules of membranes from neurons and glial cells store a wide variety of lipid messengers. Receptor-mediated events and changes in intracellular $[Ca^{2+}]$, as occurs during excitatory neurotransmission and in activity-dependent synaptic plasticity, modulate phospholipases that catalyze the release of bioactive moieties from phospholipids. These lipid messengers then

participate in intracellular and/or intercellular signaling. Bioactive lipids have significant neurobiological actions such as in the function of ion channels, receptors, neurotransmitter release, synaptic plasticity, and programs of neuronal gene expression. As a result, there is a rapid increase in the brain free fatty acid pool size, particularly of arachidonic acid (7, 8) and of the bioactive phospholipid, platelet-activating factor, (PAF, 1-O-alkyl-2-acetyl-sn-3-phosphocholine)(9, 10). Arachidonic acid is converted into a variety of biologically active derivatives through cyclooxygenation (11) and lipoxygenation (12), with these conversions being particularly enhanced during reperfusion or repeated seizures, when tissue oxygenation is coupled with an abnormally large free arachidonic acid pool. These early findings, as well as more recent ones (13) have suggested the involvement of the cytosolic, calcium dependent phospholipase A₂ (cPLA₂) in brain damage. This enzyme, which has a preference for arachidonoyl phospholipids, catalyzes the release from membranes of free arachidonic acid and of the PAF precursor, lyso PAF. The importance of cPLA₂ in brain injury is strongly supported by the recent finding that cPLA₂ knockout mice have substantially reduced infarcts and lesser neurological deficits following transient middle cerebral artery occlusion (14). While these observations do not demonstrate that cPLA₂ is directly involved in epileptogenesis, several ongoing studies are addressing this question.

Brain damage and seizures disrupt the tightly regulated events that control the production and accumulation of lipid messengers, such as free arachidonic acid, diacylglycerol and PAF under physiological conditions. Rapid activation of phospholipases, specifically of phospholipase A₂ (PLA₂) as it occurs at the onset of injury and seizures (7, 8), was predicted to play a central role in excitable membrane function and pathology (7). There are a wide variety of PLA₂s (15), and current investigations aim to define those involved in synaptic events. In addition to the role(s) of

intracellular PLA₂s in lipid messenger formation, it has recently been discovered that a low molecular weight, secretory PLA₂ synergizes glutamate-induced neuronal damage (16). Whereas pathways leading to PLA₂ activation/release are part of normal neuronal function, seizures and injury enhance these events, overproducing PLA₂-derived lipid messengers, (e.g. enzymatically produced arachidonic acid oxygenation metabolites and non-enzymatically generated lipid peroxidation products), involved in neuronal damage. Among the consequences of PLA₂ activation by seizures are alterations in mitochondrial function by the rapid increase in the brain free fatty acid pool size (e.g. uncoupling of oxidative phosphorylation from respiratory chain) (17, 18), the generation of lipid messengers and also by impairments in mitochondrial function that, in turn, lead to enhanced release of reactive oxygen species to the cytoplasm.

PAF is a very potent and short-lived lipid messenger. It is known to have a wide range of actions: as a mediator of inflammatory and immune responses, as a second messenger, and as an inducer of gene expression. Thus, in addition to its acute roles, PAF can potentially participate in long-term modifications of cellular physiology and brain function. In this article, the significance of the messenger PAF in synaptic function, including LTP, and neuronal gene expression relevant to epileptogenesis is discussed.

PAF enhances excitatory synaptic transmission and modulates synaptic plasticity.

PAF enhances glutamate release in synaptically-paired rat hippocampal neurons in culture (19). The PAF analog methylcarbaryl (mc-PAF), but not biologically inactive lyso PAF, increases excitatory synaptic responses. The inhibitory neurotransmitter γ -aminobutyric acid is unaffected by mc-PAF under these conditions. The presynaptic PAF receptor antagonist BN 52021 (see below)

blocks the mc-PAF-enhanced glutamate release. In addition, mc-PAF increases presynaptic glutamate release, since it does not augment the effects of exogenously added glutamate, and it evokes spontaneous synaptic responses characteristic of enhanced neurotransmitter release. Therefore, as a modulator of glutamate release, PAF participates in long-term potentiation (20, 21), synaptic plasticity and memory formation.

PAF, a neuronal injury messenger, contributes to excitotoxicity by enhancing glutamate release.

Seizures and ischemia increase PAF content in brain (9, 10). Furthermore, brain is endowed with a variety of degradative enzymes that rapidly convert PAF to biologically inactive lyso PAF (22-24). Presynaptic membranes display PAF binding that can be displaced by BN 52021, a terpenoid extracted from the leaf of the *Ginkgo biloba* tree, which binds preferentially to the synaptosomal site (25). It is likely that this PAF binding site is the seven transmembrane PAF receptor (26-28). BN 52021 inhibits both PAF-induced glutamate release (19) and long-term potentiation (20-21). Moreover, this antagonist is neuroprotective in ischemia-reperfusion damage in the gerbil brain (29). Taking these findings together, PAF, when overproduced at the synapse during seizures, will promote enhanced glutamate release that in turn, through the activation of postsynaptic receptors, will contribute to enhanced excitotoxicity.

PAF is a transcriptional activator of the early response gene, prostaglandin endoperoxide synthase-2 (COX-2).

In addition to its modulatory effect on synaptic transmission and neural plasticity, PAF activates receptor-mediated immediate early gene expression (30-33). Since PAF is a phospholipid

and can pass through membranes, it is rapidly taken up by cells. An intracellular binding site with very high affinity, yet pharmacologically distinct from the presynaptic site, was found in brain (25). The synthetic tetrazepine BN 50730 is selective for this intracellular site and blocks PAF-induced gene expression of the inducible form of prostaglandin G synthase in transfected cells (34).

Prostaglandin G/H synthase-2 (PGS-2, COX-2, TIS-10) catalyzes the cyclooxygenation and peroxidation of arachidonic acid into PGH_2 , the precursor of biologically active prostaglandins, thromboxanes and prostacyclin (35-36). COX-1 also catalyzes the same first committed step of the arachidonic acid cascade. COX-2, however, is expressed in response to mitogenic and inflammatory stimuli and is encoded by an early-response gene. In contrast, COX-1 expression is not subject to short-term regulation. Neurons in the hippocampus, as well as in a few other brain regions, are unlike other cells in that they display basal levels of COX-2 expression (37). This expression is modulated by synaptic activity, LTP and involves the N-methyl-D-aspartate class of glutamate receptors (37, 38).

PAF is a transcriptional activator of COX-2, as PAF induces mouse COX-2 promoter-driven luciferase activity transfected in neuroblastoma cells (NG108-15 or SH-SY5Y) and in NIH 3T3 cells. The intracellular PAF antagonist, BN 50730, inhibits PAF activation of this construct (34). Figure 1 outlines the role of PAF as a presynaptic messenger.

Sustained transcriptional upregulation of COX-2 during kainic acid-induced seizures in hippocampus.

The abundance in brain of several early-response gene transcripts shows rapid and transient increases during cerebral ischemia and after seizures (32). Several early-response genes encode

transcription factors which in turn modulate the expression of other genes, whereas others encode inducible enzymes. The glutamate analog, kainic acid, when systemically injected in rats, promotes extensive neuronal damage, and a status epilepticus-like condition (particularly in the hippocampus). It also induces early-response genes such as the transcription factor *zif-268*. COX-2 is also induced under these conditions, but there are striking differences in the magnitude and duration of the induction of COX-2 as compared with *zif-268* (Fig 2). Kainic acid-induced upregulation of COX-2 and *zif-268* transcription in hippocampus differed, as did the time course of expression following a single seizure triggered by electroconvulsive shock (39). In both conditions, the peak of COX-2 mRNA abundance was later than *zif-268*. In kainic acid treated animals, COX-2 reached a 71-fold increase over controls in 3 hours, whereas *zif-268* peaked at 1 hr with a 10-fold increase. COX-2 mRNA, 2 hr after kainic acid injection, showed a 35-fold increase in hippocampus as compared with only a 5.5 fold increase in *zif-268* (39). Also COX-2 peak in mRNA abundance was evident at 3 hrs (71-fold increase) as compared with 1 hr for *zif-268* (10-fold increase). *Zif-268* mRNA time-course of changes in the hippocampus corresponds to the expected profile of early-response genes, i.e., a rapid decrease in abundance after the peak. COX-2 on the other hand, displayed sustained upregulation for several hours after kainic acid injection (5.2 fold increase at 12 hours) (39).

Possible significance of the platelet activating factor-COX-2 intracellular signaling pathway in epileptogenesis.

A PAF-stimulated signal transduction pathway is a major component of the kainic acid-induced COX-2 expression in hippocampus. This conclusion is based upon the finding that a) PAF induces mouse COX-2 promoter-driven luciferase activity in transfected cells, and BN 50730

inhibits this effect (34); and b) BN 50730 (given intracerebroventricularly 15 min prior to kainic acid) inhibits kainic acid-induced COX-2 mRNA accumulation in hippocampus by 90% (39). Both PAF (23) and COX-2 (40) are potent mediators of the injury/inflammatory response. PAF (19-21) and COX-2 (37, 38) are also interrelated in neuronal plasticity. The PAF transcriptional activation of COX-2 may provide clues about novel neuronal cell death pathways. The antagonist BN 50730 was much less effective against *zif-268* expression. In fact, the delayed hippocampal induction of COX-2 by kainic acid precedes selective neuronal apoptosis by this agonist in this neuroanatomical region (41).

In epilepsy, the significance of the PLA_2 -related signaling triggered by seizures or injury may be part of events finely balanced between neuroprotection and neuronal cell death. The precise events that would tilt this balance toward the latter are currently being explored. It is interesting to note that PAF, being short-lived and rapidly degraded by PAF acetylhydrolase (42), is a long-term signal with consequences to neurons through COX-2 sustained expression. COX-2 is localized in the nuclear envelope and perinuclear endoplasmic reticulum. The overexpression of hippocampal COX-2 during cerebral ischemia and seizures may in turn lead to the formation of neurotoxic metabolites (e.g. superoxide). Current investigations aim to determine whether or not other messengers cooperate to enhance neuronal damage (e.g. nitric oxide) and the possible involvement of astrocytes and microglial cells. Further understanding of these potentially neurotoxic events involving lipid messengers and COX-2 will permit the identification of new therapeutic strategies for the management of epilepsy.

Acknowledgments

This work was supported by NIH grant NS23002 and DAMD-17-93-V-3013.

References

1. Sutula TP, Cavazos JE, Woodard AR (1994) Long-term structural and functional alterations induced in the hippocampus by kindling: Implication for memory dysfunction and the development of epilepsy. Hippocampus 4:254-258.
2. Sutula TP, Cascino G, Cavazos, JE, Parada I, Ramirez L. (1989) Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann Neurol 26:321-330.
3. Sloviter RS. (1994) The functional organization of the hippocampal dentate gyrus and its relevance to the pathogenesis of temporal lobe epilepsy. Ann Neurol 35:640-654.
4. Cavazos JE, Das I, Sutula TP. (1994) Neuronal loss induced in limbic pathways by kindling: evidence for induction of hippocampal sclerosis by repeated brief seizures. J Neurosci 14:3106-3121.
5. Cavazos, JE, Sutula TP. (1990) Progressive neuronal loss induced by kindling: a possible mechanism for mossy fiber synaptic reorganization and hippocampal sclerosis. Brain Res 527:1-6.
6. Cavazos, JE, Sutula TP. (1991) Progressive neuronal loss induced by kindling: a possible mechanism for mossy fiber synaptic reorganization and hippocampal sclerosis (published erratum). Brain Res 541:179.
7. Bazan NG (1970) Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. Biochim Biophys Acta 4:254-258.
8. Bazan NG, Rodriguez de Turco EB, Allan G (1995) Mediators of injury in neurotrauma: Intracellular signal transduction and gene expression. J Neurotrauma 12, 789-911.

9. Kumar R, Harvey S, Kester N, Hanahan D and Olsen, M (1988) Production and effects of platelet-activating factor in the rat brain. Biochim Biophys Acta 963, 375-383.
10. Nishida K, Markey SP (1996) Platelet-activating factor in brain regions after transient ischemia in gerbils. Stroke 27(3): 514- 518, 1996.
11. Gaudet RJ, Levine L (1980) Effect of unilateral common carotid artery occlusion on levels of prostaglandins D2, F2 and 6-keto-prostaglandin F1 in gerbil brain. Stroke 11: 648-652.
12. Prescott SM, Zimmerman GA, McIntyre TM (1990) Platelet-activating factor. J Biol Chem 265:17381-17384.
13. Rordorf G, Uemura Y, Bonventre JV (1991) Characterization of phospholipase A₂ (PLA₂) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. J Neurosci 11(6): 1829-1836.
14. Bazan NG and Allan G (1996) Platelet-activating factor is both a modulator of synaptic function and a mediator of cerebral injury and inflammation. Adv Neurol 71:475-484.
15. Dennis EA (1994) Diversity of group types, regulation and function of phospholipase A₂. J Biol Chem 269, 13057-13060.
16. Kolko M, DeCoster MA, Rodriguez de Turco E B, Bazan NG (1996) Synergy by secretory phospholipase A₂ and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J Biol Chem 271:32722-32728.
17. Bazan NG, Bazan HEP, Kennedy WG, Joel CD (1971) Regional distribution and rate of production of free fatty acids in rat brain. J Neurochem 18:1387-1393.
18. Bazan NG (1971) Changes in free fatty acids of brain by drug-induced convulsions, electroshock and anesthesia. J Neurochem 18:1379-1385.

19. Clark GD, Happel LT, Zorumski CF, Bazan NG (1992) Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. Neuron 9, 1211-1216.
20. Wieraszko A, Li G, Kornecki E, Hogan MV, Ehrlich YH (1993) Long-term potentiation in the hippocampus induced by platelet-activating factor. Neuron 10, 553-557.
21. Kato K, Clark GD, Bazan NG, Zorumski CF (1994) Platelet activating factor as a potential retrograde messenger in Ca^{1} hippocampal long-term potentiation. Nature 367, 175-179.
22. Hattori M, Arai H and Inoue, K (1993) Purification and characterization of bovine brain platelet-activating factor acetylhydrolase. J Biol Chem 268, 18748-18753.
23. Prescott SM, Zimmerman GA and McIntyre, TM (1990) Platelet-activating factor. J Biol Chem 265, 17381-17384.
24. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM (1997) Platelet-activating factor acetylhydrolases. J Biol Chem 272: 17895-17898.
25. Marcheselli VL, Rossowska M, Domingo MT, Braquet P, Bazan NG (1990) Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem 265, 9140-9145.
26. Bito H, Nakamura M, Honda Z, Izumi T, Iwatsubo T, Seyama Y, Ogura A, Kudo Y, Shimizu T (1992) Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca^{2+} in hippocampal neurons. Neuron 9: 285-294.
27. Mori M, Aihara M, Kume K, Hamanoue M, Kohsaka S, Shimizu T (1996) Predominant expression of platelet-activating factor receptor in the rat brain microglia. J Neurosci 16: 3590-3600.

28. Makamura M, Honda Z, Izumi T, Sakanaka C, Mutoh H, Minami M, Bito H, Seyama Y, Matsumoto T, Noma M, Shimizu T (1991) Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem. 266: 20400-20405, 1991.
29. Panetta T, Marcheselli VL, Braquet P, Spinnewyn B, Bazan NG (1987) Effects of a platelet-activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: Inhibition of ischemia-reperfusion induced cerebral injury. Biochem Biophys Res Comm 149:580-587.
30. Squinto SP, Block AL, Braquet P, Bazan NG (1989) Platelet-activating factor stimulates a Fos/Jun/AP-1 transcriptional signaling system in human neuroblastoma cells. J Neurosci Res 24:558-566.
31. Squinto SP, Braquet P, Block AL, Bazan NG (1990) Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes. J Mol Neurosci 2:79-84.
32. Doucet JP, Squinto SP, Bazan NG (1990) FOS-JUN and the primary genomic response in the nervous system: Physiological role and pathophysiological significance. Mol Neurobio 4:27-55.
33. Bazan NG (1990) Neuronal cell signal transduction and second messengers in cerebral ischemia. Pharmacology of Cerebral Ischemia, Proceedings of the Third International Symposium on Pharmacology of Cerebral Ischemia, J Kriegstein, H Oberpichler (eds), Wissenschaftliche Verlagsgesellschaft, Stuttgart (FRG) pp. 391-398.
34. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK, (1994) Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci 91, 5252-5256.

35. Herschman, H (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125-140.
36. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthase (cyclooxygenases) -1 and -2. J Biol Chem 271: 33157-33160.
37. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386.
38. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci 93, 2317-2321.
39. Marcheselli VL, Bazan NG (1996) Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem 271, 24794-24799.
40. Bazan NG, Botting JR Vane (Eds) (1996) New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules. William Harvey Press and Kluwer Academic Publishers, United Kingdom.
41. Pollard H, Carriaut-Marlangue C, Cantagrel S, Represa A, Robain O, Moreau J, Ben-Ari Y (1994) Kainate-induced apoptotic cell death in hippocampal neurons. Neuroscience 63:7-18
42. Bazan NG (1995) Inflammation: A signal terminator. Nature 374: 501-502.

Figure 1: Seizure-triggered signaling events linking synapse activation and COX-2 gene expression in neurons. NMDA-receptor activation by glutamate leads to phospholipase A₂ activation and the generation of PAF and of arachidonic acid. PAF is synthesized through other metabolic routes as well (19). PAF activates COX-2 gene expression through a BN-50730-sensitive intracellular site, protein kinase cascades and transcription factors. The COX-2 promoter is also a target for cytokines (activation) and glucocorticoids (inhibition). COX-2 protein then catalyzes the conversion of arachidonic acid into PGH₂, the precursor of eicosanoids. Constitutive COX-1 also catalyzes this metabolic step (modified from N. Bazan, *Primer Cerebrovascular Diseases*. M Welsh, L Chaplan, D Reis, B Siesjö, B Weir (eds), Academic Press, 1997, with permission).

Figure 2. COX-2 and *zif*-268 during kainic acid-induced seizures: Time course of changes in relative mRNA abundance and transcriptional activity in hippocampus.

(A) Relative abundance of COX-2 and *zif*-268 mRNAs compared to GAPDH mRNA, as assessed by northern analysis. (n=9-12 for each time point from 3 separate experiments, error bars $\pm$ 1 s.d.).
(B) Transcriptional activity of COX-2, COX-1 and *zif*-268 genes assessed by nuclear run-on transcription. (n=3-4 from 3 separate experiments). Data are normalized to transcriptional activity of GAPDH (modified from Marcheselli and Bazan, *J. Biol. Chem*, 1996, with permission).


Figure 3. Inhibition by intracerebroventricular injection of kainic acid-induced COX-2 protein accumulation (open bars), but not of COX-1 (closed bars) in rat hippocampus.



(A) Representative Western blots. Animals were pretreated intracerebroventricularly with BN-50730 in DMSO (experimental) or DMSO alone (control) 15 min before KA injection. Samples were


collected 6 hours after KA treatment.

(B) Quantification of Western blot data expressed as a percent increase over control (vehicle-pretreated) values. (n=10-12 from 3 separate experiments, error bars $\pm$ 1 s. d.) (from Marcheselli and Bazan, *J. Biol. Chem.*, 1996, with permission)

Figure 4. **Potential sites of drug action on the PAF - COX-2 axis.** Excitatory synaptic transmission enhances the production of PAF and of other messengers. PAF activates transcription of COX-2. COX-2 protein is located in the perinuclear region. It is not known the nature of the eicosanoids generated. PGE₂ is depicted as a product that in turn may elicit on the nuclear, paracrine and autocrine actions. Three possible drug targets are indicated as 1, 2 or 3.







③ Glucocorticoids

Stimulus

Mediator/s
(PAF)

① PAF acetyl
hydrolase

PAF-R

② Selective PAF
antagonists

Glc-R

Transcription factor

COX-2 gene

COX-2 mRNA

COX-2

PGs

AA

④ Specific COX-2
inhibitors

Effects

⑤ Prostanoid
receptor
agonists/
antagonists

